SHARE is an easy-to-search, real-time repository of HIV-related systematic reviews. Whether you’re a researcher, community member, healthcare provider or policymaker, SHARE provides a ‘one-stop shop’ for HIV-related information that has been published through a systematic review.

In addition to systematic reviews published in peer reviewed journals, SHARE also includes Rapid Response reviews produced by the Ontario HIV Treatment Network (OHTN).

Most Recent Articles

Found 5965 matching articles (Displaying on 498 pages)

SelectUnselect All Visible Articles

A systematic review of the quality of trials evaluating biomedical HIV prevention interventions shows that many lack power

2009

Purpose: Several randomized, controlled trials (RCTs) have tested strategies to prevent sexual acquisition of HIV infection, but their quality has been variable. We aimed to identify, describe, and evaluate the...

Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: A systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project

2009

Background and objective: The antiretroviral nevirapine can cause severe hepatotoxicity when used ‘off-label’ for preventing mother-to-child HIV transmission (PMTCT), newborn post-exposure prophylaxis and for pre- and post-exposure prophylaxis among non-HIV-infected...

Effects of prenatal multimicronutrient supplementation on pregnancy outcomes: A meta-analysis

2009

XST: This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results...

The effectiveness of behavioural and psychosocial HIV/STI prevention interventions for MSM in Europe: A systematic review

2009

Given the need of programme planners and policy makers for descriptions of specific interventions and quantitative estimates of intervention effects to make informed decisions concerning prevention funding and research, there...

Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: A meta-analysis

2009

OBJECTIVE: To integrate the empirical findings on the prevalence of unprotected anal intercourse (UAI) among HIV-diagnosed men who have sex with men (MSM) in the United States. METHODS: Comprehensively searching...

Evidence behind the WHO guidelines: Hospital care for children: What is the role of HIV antigen testing in infants < 12-months old?

2009

The World Health Organization has produced guidelines for the management of common illnesses in hospitals with limited resources. This series reviews the scientific evidence behind WHO’s recommendations. The WHO guidelines,...

Ethical and regulatory considerations in HIV prevention studies employing respondent-driven sampling

2009

OBJECTIVE: To review the scientific, ethical, and regulatory literature because no official guidance exists on remuneration for participant-driven recruitment or on investigators’ responsibilities for informing participants of their discordant partnerships....

HIV-related lipodystrophy in Africa and Asia

2009

No abstract.

Drug-drug interactions with raltegravir

2009

OBJECTIVE: To review all currently published drug-drug interaction studies with the HIV-integrase inhibitor raltegravir. METHODS: A PubMed search was conducted for all published reports up to August 1, 2009 as...

Linking family planning with HIV/AIDS interventions: A systematic review of the evidence

2009

OBJECTIVE: To conduct a systematic review of the literature and examine the effectiveness, optimal circumstances, and best practices for strengthening linkages between family planning and HIV interventions. DESIGN: Systematic review...

Family support for reducing morbidity and mortality in people with HIV/AIDS

2009

BACKGROUND: Care and support play a critical role in assisting people who are HIV-positive to understand the need for prevention and to enable them to protect others. As the HIV/AIDS...

How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials

2009

BACKGROUND: Ritonavir has been evaluated at boosting doses of 50–800 mg daily with seven protease inhibitors: amprenavir, atazanavir, darunavir, indinavir, lopinavir,saquinavir and tipranavir. Minimizing the boosting dose of ritonavir could...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!